Memorial Sloan Kettering Cancer Center

MiNK Therapeutics Reports Third Quarter 2023 Results

Retrieved on: 
Thursday, November 9, 2023
Hereditary diffuse gastric cancer, Survival, Periodic breathing, CGMP, NSCLC, Stomach, Inflammation, Cell, Memorial Sloan Kettering Cancer Center, Webcast, Canadian Aviation Regulations, Mink, TCR, Cancer, Autoimmunity, Therapy, Patient, HLA, Medical imaging, Pharmaceutical industry, Cryptocurrency

MiNK plans for expansion in autoimmune and inflammatory diseases.

Key Points: 
  • MiNK plans for expansion in autoimmune and inflammatory diseases.
  • NEW YORK, Nov. 09, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today reported financial results for the third quarter 2023.
  • MiNK executives will host a conference call and webcast at 8:30 a.m.
  • We ended the third quarter with a cash balance of $6.4 million as compared to $10.6 million at June 30, 2023, and $19.6 million at December 31, 2022.

Gilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-Line Treatment for Upper GI Cancers

Retrieved on: 
Monday, November 6, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, NYSE, PFS, Cancer, American Society of Clinical Oncology, Society, Science, ORR, Safety, Memorial Sloan Kettering Cancer Center, Patient, ASCO, Pharmaceutical industry

These results will be presented tomorrow during the American Society of Clinical Oncology (ASCO) Monthly Plenary Series, a virtual forum for presentation and discussion of the latest cancer research.

Key Points: 
  • These results will be presented tomorrow during the American Society of Clinical Oncology (ASCO) Monthly Plenary Series, a virtual forum for presentation and discussion of the latest cancer research.
  • Six-month landmark PFS rate was 93% for patients with PD-L1-high tumors (TAP ≥5%), 68% for patients with PD-L1-low tumors (TAP
  • Median PFS was not reached and mature PFS data are expected in the second half of next year.
  • The efficacy results including ORR and six-month PFS rates are summarized in the table below:

Gilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-line Treatment for Upper GI Cancers

Retrieved on: 
Monday, November 6, 2023
Research, Hospitals, Clinical Trials, Biotechnology, Health, Pharmaceutical, Other Science, Science, Oncology, NYSE, PFS, Cancer, American Society of Clinical Oncology, Society, Multimedia, ORR, Safety, Memorial Sloan Kettering Cancer Center, Patient, ASCO, Pharmaceutical industry

These results will be presented tomorrow during the American Society of Clinical Oncology (ASCO) Monthly Plenary Series, a virtual forum for presentation and discussion of the latest cancer research.

Key Points: 
  • These results will be presented tomorrow during the American Society of Clinical Oncology (ASCO) Monthly Plenary Series, a virtual forum for presentation and discussion of the latest cancer research.
  • The domvanalimab-containing regimen showed an ORR of 80% in patients with PD-L1-high tumors (tumor activity positivity (TAP) ≥5%), 46% in patients with PD-L1-low tumors (TAP
  • Median PFS was not reached and mature PFS data are expected in the second half of next year.
  • The efficacy results including ORR and six-month PFS rates are summarized in the table below:

BioReference® Signs On as the First Laboratory to Use MSK-ACCESS® Powered with SOPHiA DDM™

Retrieved on: 
Tuesday, November 7, 2023
Urology, Health, Biomarker, Sophia Genetics, MSK, Artificial intelligence, Database, Sophia, Clinical trial, Memorial Sloan Kettering Cancer Center, Cancer, Risk assessment, Algorithm, OPKO Health, Liquid biopsy, Patient, GENETICS, Medical imaging

BOSTON and ELMWOOD PARK, N.J. and ROLLE, Switzerland, Nov. 7, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that BioReference® Health, LLC, an OPKO Health, Inc. company and full-service laboratory that processes more than 12 million tests annually, will implement SOPHiA GENETICS' technology and add MSK-ACCESS® liquid biopsy to its test suite. With the implementation of SOPHiA GENETICS, BioReference will be the first laboratory globally to adopt MSK-ACCESS® powered with SOPHiA DDM™. The offering will be commercially available for ordering by healthcare providers through BioReference, and its specialty division, GenPath® Oncology in 2024.

Key Points: 
  • With the implementation of SOPHiA GENETICS, BioReference will be the first laboratory globally to adopt MSK-ACCESS® powered with SOPHiA DDM™.
  • The offering will be commercially available for ordering by healthcare providers through BioReference, and its specialty division, GenPath® Oncology in 2024.
  • BioReference® Health will implement SOPHiA GENETICS' technology and add MSK-ACCESS® liquid biopsy to its test suite.
  • For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM , or connect on X (formerly known as Twitter), LinkedIn , Facebook , and Instagram .

BioReference® Signs On as the First Laboratory to Use MSK-ACCESS® Powered with SOPHiA DDM™

Retrieved on: 
Tuesday, November 7, 2023
Urology, Health, Biomarker, Sophia Genetics, MSK, Artificial intelligence, Database, Sophia, Clinical trial, Memorial Sloan Kettering Cancer Center, Cancer, Risk assessment, Algorithm, OPKO Health, Liquid biopsy, Patient, GENETICS, Medical imaging

BOSTON and ELMWOOD PARK, N.J., and ROLLE, Switzerland, Nov. 7, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that BioReference® Health, LLC, an OPKO Health, Inc. company and full-service laboratory that processes more than 12 million tests annually, will implement SOPHiA GENETICS' technology and add MSK-ACCESS® liquid biopsy to its test suite. With the implementation of SOPHiA GENETICS, BioReference will be the first laboratory globally to adopt MSK-ACCESS® powered with SOPHiA DDM™. The offering will be commercially available for ordering by healthcare providers through BioReference, and its specialty division, GenPath® Oncology in 2024.

Key Points: 
  • With the implementation of SOPHiA GENETICS, BioReference will be the first laboratory globally to adopt MSK-ACCESS® powered with SOPHiA DDM™.
  • The offering will be commercially available for ordering by healthcare providers through BioReference, and its specialty division, GenPath® Oncology in 2024.
  • MSK-ACCESS® powered with SOPHiA DDM™ is being designed to align with the most up-to-date guidelines and clinical trial data, reflecting major biologically actionable biomarkers.
  • For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM , or connect on X , LinkedIn , Facebook , and Instagram .

Myriad Genetics Reports Third Quarter 2023 Financial Results; Generates Double-Digit Revenue Growth; Raises 2023 Revenue Guidance and Introduces 2024 Revenue Guidance

Retrieved on: 
Monday, November 6, 2023
PRS, UnitedHealth Group, Memorial Sloan Kettering Cancer Center, Cancer, Policy, ARR, Genetic testing, Patent, MDD, CDX, Radiation, Myriad Genetics, Family, Physician, DSM-IV codes, Genetics, Prostate cancer, MSK, GAAP, Research, ADT, Circulating tumor DNA, Metabolism, Meta-analysis, Ravgen, MRD, Women's health, Biopsy, Breast cancer, Risk assessment, Breast, Woman, Depression, ABL, Anxiety, Google Images, Attention deficit hyperactivity disorder, Neoplasm, Metastasis, DNA, Video game, Medical imaging, Pharmaceutical industry, Vaccine, Dietary supplement, Birth control, Medical device, Bank, Risk, Patient, Oncology

SALT LAKE CITY, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced financial results for its third quarter ended September 30, 2023. The Company also provided an update on its business performance and 2023 financial guidance.

Key Points: 
  • GAAP gross margins of 70.0% in the third quarter of 2023; adjusted gross margins for the third quarter of 2023 was 70.4%, an increase of 140.0 basis points from the second quarter of 2023.
  • The Myriad Genetics Oncology business provides hereditary cancer testing, including the MyRisk® hereditary cancer test for patients who have cancer.
  • Prolaris continued to see healthy demand as third quarter testing revenue and volumes grew 18% and 9% year-over-year, respectively.
  • 16_suppl (June 01, 2023)5030
    Myriad Genetics updates its 2023 revenue and non-GAAP financial guidance, as stated in the table below.

SELLAS Life Sciences Presents Positive Key Immunobiological and Clinical Data from Phase 1/2 Trial of Galinpepimut-S (GPS) in Combination with Keytruda® in WT1+ Platinum-Resistant Advanced Ovarian Cancer at the International Gynecologic Cancer Society 202

Retrieved on: 
Monday, November 6, 2023
SLS, Neoplasm, Survival, WT1, GPS, Ovarian cancer, Biomarker, DCR, Pembrolizumab, PFS, CPS, SD, Disease, Memorial Sloan Kettering Cancer Center, Cancer, ORR, Safety, Progression-free survival, Patient, OS, Associate, Pharmaceutical industry, Medical imaging, Health insurance

GPS is an HLA-unrestricted heteroclitic immunotherapy against WT1, an antigen highly expressed in more than 85% of patients with ovarian cancer.

Key Points: 
  • GPS is an HLA-unrestricted heteroclitic immunotherapy against WT1, an antigen highly expressed in more than 85% of patients with ovarian cancer.
  • This Phase 1/2 trial was an open-label, multicenter, multi-arm basket study examining the effects of the combination of GPS and pembrolizumab in patients with measurable advanced selected cancers.
  • In the ovarian cancer arm of the study, the effect of the combination was investigated in patients with measurable WT1+ platinum-resistant ovarian cancer relapsed after or refractory to 1st/2nd -or later- line of therapy.
  • Today’s presentation reported clinical efficacy and safety results as well as demographic and disease parameter data in a total of 16 evaluable patients.

MiNK Therapeutics Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023

Retrieved on: 
Friday, November 3, 2023
Neoplasm, Nivolumab, MSI, Cell, Testicular cancer, Memorial Sloan Kettering Cancer Center, Neurotoxicity, SITC, Immunotherapy, Cytokine release syndrome, Mink, Annual general meeting, Lung cancer, Society, Cancer, Therapy, Patient, HLA, Failure, Phosphorus, Vaccine, Pharmaceutical industry, Medical imaging

AgenT-797 showed long-term persistence and induced a potent anti-tumor response, including increased infiltration of cytotoxic immune cells into tumors.

Key Points: 
  • AgenT-797 showed long-term persistence and induced a potent anti-tumor response, including increased infiltration of cytotoxic immune cells into tumors.
  • AgenT-797 was detected in the periphery for up to 6 months and persistence was independent of HLA matching.
  • An increased level of immune cell tumor infiltration and neoantigen driven expansion of anti-tumor cytotoxic T cells was observed following administration.
  • Expansion of clinical programs are underway in additional solid tumor settings, including relapsed/refractory gastric cancer.

Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseases

Retrieved on: 
Wednesday, November 1, 2023
T helper 17 cell, Psoriasis, Medical research, Pulmonary fibrosis, Publication, Scleroderma, Preprint, Immunodeficiency, TGF, RNA, Cytokine, Fibrosis, GVHD, Research, Inflammation, INSERM, ITK, Induction, MMP2, Hôpital Cochin, Systemic, Clinical trial, Asthma, Atopic dermatitis, Cancer, IL-5, Memorial Sloan Kettering Cancer Center, Lymphoma, Chronic obstructive pulmonary disease, COPD, Enteropathy-associated T-cell lymphoma, Lupus, Extractive metallurgy, Vaccine, Rheumatology, Corvus, T helper cell

BURLINGAME, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the publication of preclinical data that demonstrated the potential of ITK inhibition as a novel approach to treat T cell-mediated inflammatory and immune diseases. Corvus’ ITK inhibitors include soquelitinib (formerly known as CPI-818), which was used in the preclinical studies and is currently in clinical trials for oncology indications, and several next-generation molecules that are being optimized for use in a variety of inflammatory and immune disease indications.

Key Points: 
  • “Our research on soquelitinib and selective ITK inhibition is uncovering valuable new information about immune function and the role of ITK in different diseases,” said James Rosenbaum, M.D., senior vice president of research at Corvus.
  • “The activity of soquelitinib in various inflammatory and immune disease models highlights the essential role of ITK in multiple T cell functions.
  • The publication is now available online as a preprint at bioRxiv.org and on the Publications and Presentations page of the Corvus website.
  • With this new publication, we further demonstrate the wide range of opportunities for ITK inhibition across specific indications with ongoing patient needs for new therapies.

Verastem Oncology Announces Efficacy and Safety Data of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) in Heavily Pretreated Patient Population

Retrieved on: 
Monday, November 6, 2023
Research, General Health, Pharmaceutical, Oncology, Consumer, Clinical Trials, Science, Women, Biotechnology, FDA, Other Science, Health, Ovarian cancer, RAMP, Standard of care, SOC, Topotecan, Food, Lot, Soda Springs, The Annual Global Orgasm for Peace, Safety, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Society, Paclitaxel, Disease, Memorial Sloan Kettering Cancer Center, FRAME, ORR, Letrozole, RECIST, Part, Cancer, Patient, Anastrozole, Verastem Oncology, Pharmaceutical industry

Verastem Oncology (Nasdaq: VSTM) (the “Company”), a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced today results of the efficacy and safety of avutometinib and defactinib in recurrent low-grade serous ovarian cancer (LGSOC) following prior systemic therapy.

Key Points: 
  • Verastem Oncology (Nasdaq: VSTM) (the “Company”), a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced today results of the efficacy and safety of avutometinib and defactinib in recurrent low-grade serous ovarian cancer (LGSOC) following prior systemic therapy.
  • The analysis also evaluated efficacy in the context of best response to most recent prior treatment in the metastatic/recurrent setting.
  • The safety profiles of avutometinib and defactinib were similar in the less and more heavily pretreated subgroups and both analyses were consistent with previously reported safety data.
  • Dr. Grisham is a paid consultant for Verastem Oncology.